Belzutifan (trade name Welireg) is a drug specifically used to treat diseased tissues associated with von Hippel-Lindau (VHL) syndrome. This article will discuss its basic information, purchase considerations, and pharmacokinetic properties, with the aim of providing detailed information for patients and their families.
The purchase channel of Belzutifan
Understanding the basic information of a drug is a basic step in the selection and use of a treatment regimen, and it is important to understand its mechanism of action, its scope of application, and purchase channels.
R&D & Approval History
Belzutifan is developed and manufactured by Merck & Co., and received first marketing approval from the U.S. Food and Drug Administration (FDA) on August 13, 2021. The drug is indicated for the treatment of adult patients with VHL syndrome who require treatment of concomitant renal cell disease (RCC), central nervous system (CNS) hemangioblastoma, or pancreatic neuroendocrine lesion tissue (pNET), but does not require immediate surgery.
The main purchase channel
The main active ingredient of Welireg is Belzutifan, which is available in tablet form. It is currently available in China and can be purchased through large hospitals or pharmacies.
Familiarity with the purchase channels of Belzutifan can help patients to purchase the drug smoothly.
Precautions for the purchase of Belzutifan
Understanding the details of the purchase process can help patients get the drugs they need more smoothly and avoid unnecessary risks.
Pricing and availability
Lucius's generic version of Belzutifan is available in 40mg*90 tablets and costs about $888. Since the drug has not been marketed in China and is not covered by medical insurance, domestic patients may need to purchase drugs overseas or participate in clinical trials to obtain the drug.
Legal and Security Considerations
When purchasing Belzutifan, it is necessary to comply with relevant laws and regulations and make it clear that the source of the drug is legal. In addition, considering the problems that may arise during transportation, it is advisable to choose a reputable supplier and pay attention to the expiration date and storage conditions of the drug.
Understanding the precautions for purchasing can not only help patients obtain drugs smoothly, but also effectively reduce potential risks and maintain the safety of medications.
Pharmacokinetics of Belzutifan
Understanding the pharmacokinetic properties of drugs can help optimize treatment options, improve efficacy, and reduce side effects.
Absorption and distribution
The median Tmax of Belzutifan appears 1-2 hours after administration, indicating rapid absorption into the circulatory system. The distribution of the drug in the body is affected by a variety of factors, including the patient's liver and kidney function.
Metabolism and excretion
Belzutifan is metabolized primarily by UGT2B17 and CYP2C19 enzymes, so caution should be taken when using with inhibitors of these enzymes, as this may increase the blood concentration of the drug and thus increase the risk of adverse effects. Regarding its specific excretion route and rate, current research shows that it is excreted mainly through urine.
An in-depth understanding of the pharmacokinetics of Belzutifan can help healthcare professionals adjust the dose more precisely, while also helping patients understand how to use drugs appropriately according to their condition.
